Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
about
Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using KinectAnimal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyThe TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug developmentGuidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translationalIndividualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy24 month longitudinal data in ambulant boys with Duchenne muscular dystrophyQuantitative muscle ultrasound in Duchenne muscular dystrophy: a comparison of techniques.Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension StudyBlunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy.The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences.Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by KinectThe 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies.Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of NeurologyMulticenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trialPrednisolone improves walking in Japanese Duchenne muscular dystrophy patientsValidity, Reliability, and Sensitivity of a 3D Vision Sensor-based Upper Extremity Reachable Workspace Evaluation in Neuromuscular DiseasesLooking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies.Eteplirsen in the treatment of Duchenne muscular dystrophyA critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy.Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Dystrophin induced cognitive impairment: mechanisms, models and therapeutic strategiesDeveloping a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.Quantitative Ultrasound Assessment of Duchenne Muscular Dystrophy Using Edge Detection Analysis.Health-Related Quality of Life in Children with DuchenneMuscular Dystrophy: A Review.Electrical impedance myography for assessment of Duchenne muscular dystrophy.Fatherhood: experiences of fathers of boys diagnosed with Duchenne Muscular Dystrophy.Why short stature is beneficial in Duchenne muscular dystrophy.Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese-enhanced magnetic resonance imaging.Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study.Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test.Computer task performance by subjects with Duchenne muscular dystrophy.International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012.Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system.Electrical impedance myography for the assessment of children with muscular dystrophy: a preliminary study.
P2860
Q27332140-15E967C6-FBDD-49D0-B24E-9460D0C5D468Q28084979-53B80C4B-E652-40DF-AF6A-AE324900A1C7Q28088277-783A499D-0E0C-45A7-92FE-E838D9421507Q28485060-84431863-5910-4244-8A07-AD32F70C7972Q28554686-6F3162DA-9EF8-4714-B9E7-BA5503EC8BDBQ30000819-05EF861B-678C-4F7D-9A70-58B5390720E2Q30392474-715750CD-4508-4C03-AA50-F49379159FACQ33435110-2C26159A-1492-4632-AB51-FE3B9F760E85Q34048279-05081F8B-17A8-46D4-9869-E40079A68B21Q34103360-8320090F-19D9-4A7B-B0EA-DF06E4772DD8Q34151082-DF19D76F-8B12-448A-9DCF-4FF5C43265B7Q34517198-B0A14373-1454-4F83-A2C6-19DD5580DDD2Q34836557-F306FE96-C4B0-42AF-B672-569BE5D133DEQ35749826-E67EB9B8-D99B-4780-B99B-0DAD2EE318D0Q36097194-56065DC4-6330-4E88-B718-9A050BEDC893Q36638831-C7B07770-C435-4B78-9EDA-0B11409E3AD6Q37114363-57E62D08-CD13-4835-A3AB-BB1B713F56BBQ37150891-0B7C93C5-6368-458D-A066-E779F3115E2EQ37349765-B7C46E31-CE1F-4414-9146-55949DD2C1AEQ37410966-9E02F088-A445-4798-B0CD-2C7698A40D74Q37589787-3726F1C1-D7AC-4E37-97B4-2CE7165E6879Q37682676-29C5E6CC-40C6-44E7-A91F-672DDF9AB872Q38019990-7C3182A7-574B-4A3E-A096-3C2C16691364Q38115148-0251C51C-F26F-4E07-97D5-E0A04F5473FAQ38302852-7F7572CE-BBD8-4169-90DA-99AB7B22A9FEQ38541264-FED37CF6-A867-4A03-A577-8B192EAF3637Q38712657-7A54B2C1-E4D9-4BF6-8BDE-87F0E98C82BEQ38897227-D689A3E8-567F-407B-AB6B-9E9C9CAA03A8Q39012023-523FF908-FD3E-4DFA-B964-DB6575C6049FQ39026682-6AEB62D4-BA45-410E-B4BC-5072C25E218CQ39247345-F25F3BCB-3009-4731-A699-27A20E2A1F90Q39376754-BCAA0461-2011-41B7-A197-85894BBE9946Q39459441-C2443F97-969A-44F4-9B67-6DA8F52B2C06Q39847054-41861030-F520-47A6-976B-8F462981055CQ40198410-67B8287A-5410-4420-BEBB-4576382614C3Q41145500-FD6EE323-1CF9-4576-82E9-CDFC7D1DCE04Q41293319-7AC7ED32-E91A-49D4-AB85-1A9F41B4E53DQ41431256-1F7FC961-7010-4F98-97E8-D3B7BBEF8377Q42454269-156F6B20-BB9C-46E5-92CF-28D8964F134FQ43077577-3D962EE5-82BF-40F3-956C-6F89E3461AFB
P2860
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Clinical outcome measures for ...... ational Working Group meetings
@ast
Clinical outcome measures for ...... ational Working Group meetings
@en
type
label
Clinical outcome measures for ...... ational Working Group meetings
@ast
Clinical outcome measures for ...... ational Working Group meetings
@en
prefLabel
Clinical outcome measures for ...... ational Working Group meetings
@ast
Clinical outcome measures for ...... ational Working Group meetings
@en
P2860
P356
P1476
Clinical outcome measures for ...... ational Working Group meetings
@en
P2093
Edward Connor
Kate Bushby
P2860
P304
P356
10.4155/CLI.11.113
P577
2011-09-01T00:00:00Z